title: Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation.
abstract: Chronic myeloid leukaemia is a haemopoietic stem cell disorder, the hallmark of which is the expression of the Bcr-Abl Protein Tyrosine Kinase (PTK). We have previously reported that activation of a temperature sensitive Bcr-Abl PTK in the multipotent haemopoietic cell line FDCP-Mix for short periods resulted in subtle changes including, a transient suppression of apoptosis and no inhibition of differentiation. In contrast, activation of the Bcr-Abl PTK for 12 weeks results in cells that display a delay in differentiation at the early granulocyte stage. Flow cytometric analysis also indicates that the expression of cell surface differentiation markers and nuclear morphology are uncoupled. Furthermore, a significant number of the mature neutrophils display abnormal morphological features. Prolonged exposure to Bcr-Abl PTK results in interleukin-3 independent growth and decreased p53 protein levels. FDCP-Mix cells expressing a dominant negative p53 and p53null FDCP-Mix cells demonstrate that the reduction in p53 is causally related to the delay in development. Returning the cells to the restrictive temperature restores the p53 protein levels, the growth factor dependence and largely relieves the effects on development. We conclude that prolonged Bcr-Abl PTK activity within multipotent cells results in a reduction of p53 that drives a delayed and abnormal differentiation.
authors: Leukaemia Research Fund Cellular Development Unit, UMIST, Manchester, UK.
authors: A
authors: A
authors: Pierce
authors: E
authors: E
authors: Spooncer
authors: S
authors: S
authors: Wooley
authors: C
authors: C
authors: Dive
authors: J M
authors: JM
authors: Francis
authors: J
authors: J
authors: Miyan
authors: P J
authors: PJ
authors: Owen-Lynch
authors: T M
authors: TM
authors: Dexter
authors: A D
authors: AD
authors: Whetton
mesh_terms: D000818:Animals; D002454:Cell Differentiation / Q000502:physiology; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D020868:Gene Silencing; D016158:Genes, p53; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000201:enzymology* / Q000473:pathology; D051379:Mice; D022423:Myeloid Cells / Q000166:cytology / Q000201:enzymology*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D013696:Temperature; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*
chemical_list: D007377:Interleukin-3; D016159:Tumor Suppressor Protein p53; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl